{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:27:08Z","timestamp":1790375228635,"version":"4.1.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Clin Pathol"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1309\/3wg32yramq7rb9d4","type":"journal-article","created":{"date-parts":[[2007,3,30]],"date-time":"2007-03-30T20:18:38Z","timestamp":1175285918000},"page":"534-544","source":"Crossref","is-referenced-by-count":51,"title":["Lineage Determination of CD20\u2013 B-Cell Neoplasms"],"prefix":"10.1093","volume":"126","author":[{"given":"Peiguo G.","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Loera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence M.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,10,1]]},"reference":[{"key":"E00001","doi-asserted-by":"crossref","unstructured":"Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29:1411-1421.","DOI":"10.1097\/01.pas.0000180856.74572.73"},{"key":"E00002","doi-asserted-by":"crossref","unstructured":"Garcia-Cosio M, Santon A, Martin P, et al. Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphoma. Mod Pathol. 2004;17:1531-1538.","DOI":"10.1038\/modpathol.3800227"},{"key":"E00003","doi-asserted-by":"crossref","unstructured":"Bennett JM, Catovsky D, Daniel MT. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:626-629.","DOI":"10.7326\/0003-4819-103-4-620"},{"key":"E00004","doi-asserted-by":"crossref","unstructured":"Nutt SL, Heavey B, Rolink AG, et al. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature. 1999;401:556-562.","DOI":"10.1038\/44076"},{"key":"E00005","doi-asserted-by":"crossref","unstructured":"Krenacs L, Himmelmann AW, Quintanilla-Martinez L. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood. 1998;92:1308-1316.","DOI":"10.1182\/blood.V92.4.1308"},{"key":"E00006","doi-asserted-by":"crossref","unstructured":"Samardzic T, Gerlach J, Muller K, et al. CD22 regulates early B cell development in BOB.1\/OBF.1-deficient mice. Eur J Immunol. 2002;32:2481-2489.","DOI":"10.1002\/1521-4141(200209)32:9<2481::AID-IMMU2481>3.0.CO;2-C"},{"key":"E00007","doi-asserted-by":"crossref","unstructured":"Pilozzi E, Pulford K, Jones M, et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol. 1998;186:140-143.","DOI":"10.1002\/(SICI)1096-9896(1998100)186:2<140::AID-PATH149>3.0.CO;2-Y"},{"key":"E00008","unstructured":"Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999;5:611-615."},{"key":"E00009","doi-asserted-by":"crossref","unstructured":"Pijuan L, Vicioso L, Bellosillo B, et al. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection. Am J Surg Pathol. 2005;29:1399-1403.","DOI":"10.1097\/01.pas.0000169496.04283.b9"},{"key":"E00010","doi-asserted-by":"crossref","unstructured":"Pileri S, Gaidano G, Zinzani PL. Primary mediastinal B-cell lymphoma: high frequency of bcl-6 mutations and consistent expression of the transcription factors OCT.2 and BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol. 2003;162:243-253.","DOI":"10.1016\/S0002-9440(10)63815-1"},{"key":"E00011","doi-asserted-by":"crossref","unstructured":"Meeker T, Lowder J, Cleary ML, et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med. 1985;312:1658-1665.","DOI":"10.1056\/NEJM198506273122602"},{"key":"E00012","doi-asserted-by":"crossref","unstructured":"Maloney DG, Brown S, Czerwinski DK, et al. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood. 1992;80:1502-1510.","DOI":"10.1182\/blood.V80.6.1502.1502"},{"key":"E00013","doi-asserted-by":"crossref","unstructured":"Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101-106.","DOI":"10.1182\/blood.V97.1.101"},{"key":"E00014","unstructured":"Hainsworth JD. Rituximab as first-line systemic therapy for patients with low-grade lymphoma. Semin Oncol. 2000;27:25-29."},{"key":"E00015","doi-asserted-by":"crossref","unstructured":"Byrd JC, Murphy T, Howard RS, et al. Rituximab using a three weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrated clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153-2164.","DOI":"10.1200\/JCO.2001.19.8.2153"},{"key":"E00016","unstructured":"Maloney DG. Preclinical and phase I and II trials of rituximab. Semin Oncol. 2001;26:74-78."},{"key":"E00017","doi-asserted-by":"crossref","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.","DOI":"10.1056\/NEJMoa011795"},{"key":"E00018","doi-asserted-by":"crossref","unstructured":"Alvaro-Naranjo T, Jaen-Martinez J, Guma-Padro J, et al. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Ann Hematol. 2003;82:585-588.","DOI":"10.1007\/s00277-003-0694-1"},{"key":"E00019","unstructured":"Davis TA, Maloney DG, Grillo-Lopez AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res. 2000;6:2644-2652."},{"key":"E00020","doi-asserted-by":"crossref","unstructured":"Kennedy GA, Tey SK, Cobcroft R, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol. 2002;119:412-416.","DOI":"10.1046\/j.1365-2141.2002.03843.x"},{"key":"E00021","unstructured":"Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999;5:611-615."},{"key":"E00022","doi-asserted-by":"crossref","unstructured":"Chu PG, Chen YY, Molina A, et al. Recurrent B-cell neoplasms after rituximab therapy: an immunohistochemical and genotypic study. Leuk Lymphoma. 20052;43:2335-2341.","DOI":"10.1080\/1042819021000040044"},{"key":"E00023","doi-asserted-by":"crossref","unstructured":"Foran JM, Norton AJ, Micallef IN, et al. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol. 2001;114:881-883.","DOI":"10.1046\/j.1365-2141.2001.03019.x"},{"key":"E00024","doi-asserted-by":"crossref","unstructured":"Yokose N, Ogata K, Sugisaki Y, et al. CD20-positive T cell leukemia\/lymphoma: case report and review of the literature. Ann Hematol. 2001;80:372-375.","DOI":"10.1007\/s002770100297"},{"key":"E00025","doi-asserted-by":"crossref","unstructured":"Yao X, Teruya-Feldstein J, Raffeld M, et al. Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. Mod Pathol. 2001;14:105-110.","DOI":"10.1038\/modpathol.3880265"},{"key":"E00026","unstructured":"Chang KL, Arber DA, Weiss LM. CD20: A review. Appl Immunohistochem. 1996;4:1-15."},{"key":"E00027","doi-asserted-by":"crossref","unstructured":"Dong HY, Scadden DT, de Leval L, et al. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol. 2005;29:1633-1641.","DOI":"10.1097\/01.pas.0000173023.02724.1f"},{"key":"E00028","doi-asserted-by":"crossref","unstructured":"Knowles DM, Inghirami G, Ubriaco A, et al. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and possible pathogenetic role of the Epstein-Barr virus. Blood. 1989;73:792-799.","DOI":"10.1182\/blood.V73.3.792.bloodjournal733792"},{"key":"E00029","doi-asserted-by":"crossref","unstructured":"Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996;88:645-656.","DOI":"10.1182\/blood.V88.2.645.bloodjournal882645"},{"key":"E00030","doi-asserted-by":"crossref","unstructured":"Wienands J. The B-cell antigen receptor: formation of signaling complexes and the function of adaptor protein. Curr Top Microbiol Immunol. 2000;245:53-76.","DOI":"10.1007\/978-3-642-57066-7_2"},{"key":"E00031","doi-asserted-by":"crossref","unstructured":"Van Noesel CJM, Brouns GS, van Schijndel GMW, et al. Comparison of human B-cell antigen receptor complexes: membrane-expressed forms of immunoglobulin (Ig) M, IgD, and IgG are associated with structurally related heterodimers. J Exp Med. 1992;175:1511-1519.","DOI":"10.1084\/jem.175.6.1511"},{"key":"E00032","doi-asserted-by":"crossref","unstructured":"van Noesel CJ, van Lier RA, Cordell J, et al. The membrane IgM-associated heterodimer on human B cells is a newly defined B-cell antigen that contains the protein product of the mb-1 gene. J Immunol. 2000;146:3881-3888.","DOI":"10.4049\/jimmunol.146.11.3881"},{"key":"E00033","doi-asserted-by":"crossref","unstructured":"Mason DY, Cordell JL, Brown MH, et al. CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. Blood. 1995;86:1453-1459.","DOI":"10.1182\/blood.V86.4.1453.bloodjournal8641453"},{"key":"E00034","doi-asserted-by":"crossref","unstructured":"Chu PG, Arber DA. CD79: a review. Appl Immunohistochem Mol Morphol. 2001;9:97-106.","DOI":"10.1097\/00129039-200106000-00001"},{"key":"E00035","doi-asserted-by":"crossref","unstructured":"Kozlov I, Beason K, Yu C, et al. CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity. Cancer Genet Cytogenet. 2005;163:62-67.","DOI":"10.1016\/j.cancergencyto.2005.06.002"},{"key":"E00036","unstructured":"Arber DA, Jenkins KA, Slovak ML. CD79 alpha expression in acute myeloid leukemia: high frequency of expression in acute promyelocytic leukemia. Am J Pathol. 1996;149:1105-1110."},{"key":"E00037","doi-asserted-by":"crossref","unstructured":"Torlakovic E, Torlakovic G, Nguyen PL, et al. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol. 2002;26:1343-1350.","DOI":"10.1097\/00000478-200210000-00011"},{"key":"E00038","doi-asserted-by":"crossref","unstructured":"Staudt LM, Clerc RG, Singh H, et al. Cloning of a lymphoid-specific cDNA encoding a protein binding the regulatory octamer DNA motif. Science. 1988;241:577-580.","DOI":"10.1126\/science.3399892"},{"key":"E00039","doi-asserted-by":"crossref","unstructured":"Henderson A, Calame K. Transcriptional regulation during B cell development. Annu Rev Immunol. 1998;16:163-200.","DOI":"10.1146\/annurev.immunol.16.1.163"},{"key":"E00040","doi-asserted-by":"crossref","unstructured":"Schebesta M, Heavey B, Busslinger M. Transcriptional control of B-cell development. Curr Opin Immunol. 2002;14:216-223.","DOI":"10.1016\/S0952-7915(02)00324-2"},{"key":"E00041","unstructured":"Saez AI, Artiga MJ, Sanchez-Beato M, et al. Analysis of octamer-binding transcription factors Oct2 and Oct1 and their coactivator BOB.1\/OBF.1 in lymphomas. Mod Pathol. 2002;15:211-220."},{"key":"E00042","doi-asserted-by":"crossref","unstructured":"Marafioti T, Ascani S, Pulford K, et al. Expression of B-lymphocyte-associated transcription factors in human T-cell neoplasms. Am J Pathol. 2003;162:861-871.","DOI":"10.1016\/S0002-9440(10)63882-5"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/126\/4\/534\/4987748\/ajcpath126-0534.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T07:09:30Z","timestamp":1683788970000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article-lookup\/doi\/10.1309\/3WG32YRAMQ7RB9D4"}},"subtitle":["An Immunohistochemical Study"],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":42,"aliases":["10.1309\/3wg3-2yra-mq7r-b9d4"],"journal-issue":{"issue":"4","published-online":{"date-parts":[[2006,10,1]]},"published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1309\/3WG32YRAMQ7RB9D4"],"URL":"https:\/\/doi.org\/10.1309\/3wg32yramq7rb9d4","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}